

Duomyxin	NL/V/0381/001/DC
Domes Pharma	DCP
	Publicly available assessment report



College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

**P.O. Box 8275, 3503 RG Utrecht, NL
(The Netherlands)**

**DECENTRALISED
PROCEDURE**

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
MEDICINAL PRODUCT**

Duomyxin NL/V/0381/001/DC

Duomyxin	NL/V/0381/001/DC
Domes Pharma	DCP
	Publicly available assessment report

MODULE 1

PRODUCT SUMMARY

EU Procedure number	NL/V/0381/001/DC
Name, strength and pharmaceutical form	Duomyxin, Eye drops, powder and solvent for solution. 1 mL contains: Neomycin (as sulfate).....3,400 IU and Polymyxin B (as sulfate).....10,000 IU
Applicant	Dômes Pharma, 3 Rue André Citroën, 63430 Pont Du Château, France
Active substance(s)	Neomycin (as sulfate) + Polymyxine-B (as sulfate)
ATC Vetcode	QS01AA30
Target species	dogs, cats
Indication for use	Treatment of superficial eye infections caused by bacteria susceptible to polymyxin B and neomycin based on susceptibility testing.

Duomyxin	NL/V/0381/001/DC
Domes Pharma	DCP
	Publicly available assessment report

MODULE 2

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

Duomyxin	NL/V/0381/001/DC
Domes Pharma	DCP
	Publicly available assessment report

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Hybrid application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	23 November 2022
Concerned Member States for original procedure	Old CMS: AT, BE, DE, DK, ES, FI, IE, IT, LU, NO, PT. New CMS: EL, PL, RO, SE

I. SCIENTIFIC OVERVIEW

DUOMYXIN, 3 400 IU/ml / 10 000 IU/ml, Eye drops, powder and solvent for solution for dogs and cats is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the reactions observed are indicated in the SPC.

DUOMYXIN is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

The quality / safety / efficacy aspects of DUOMYXIN is based on bioequivalence with the (EU) Reference Product Tevemyxine collyre (MA no.: FR/V/7976637 9/1992).

Warnings statements and precautions are adopted from the (EU) Reference Product.

Additional statements have been added, based on increased knowledge and the current state of science. Adverse events and contraindications are indicated in the SPC.

II. QUALITY ASPECTS

A. *Qualitative and quantitative particulars*

The veterinary medicinal product Duomyxin eye drops lyophilizate and solvent for solution contains Neomycin sulfate 3,400 IU /ml and Polymyxin B sulfate 10,000 IU/ml (when reconstituted). The excipients of the lyophilized product are Dextran 70 for injection, Disodium edetate and water for injections; the excipients of the solvent product are Dextran 70 for injection, Sodium dihydrogen phosphate dihydrate, Disodium phosphate dodecahydrate, Sodium chloride, Benzalkonium chloride and water for injections.

The container/closure system of the lyophilized product is a 10 ml vial, made of amber glass type I, closed with a chlorobutyl stopper and sealed with an aluminium cap. The container/closure system of the solvent product is a 5 ml LDPE bottle without additives, topped with a dropper made of LDPE without additives and closed with a white screw cap in HDPE

Duomyxin	NL/V/0381/001/DC
Domes Pharma	DCP
	Publicly available assessment report

with additives. A PVC dropper with a white cap made of HDPE is packed separately. The submitted extractable studies from primary packaging materials and solvent are acceptable and no further control measures are deemed required.

The choice of the formulation and presence of preservative are justified.

The veterinary medicinal product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

The product is manufactured including non-standard manufacturing techniques. Suitable validation results have been provided.

C. Control of Starting Materials

The active substances are Neomycin sulfate and Polymyxin B sulfate, two established active substances described in the European Pharmacopoeia. The active substances Neomycin sulfate and Polymyxin B sulfate are manufactured in accordance with the principles of good manufacturing practice.

A copy of the Certificates of Suitability have been provided in the dossier.

The active substance specifications are considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with these specifications have been provided.

The excipients are in conformity with the Ph.Eur. requirements.

None of the starting materials used are affected by the Note for Guidance on TSE/BSE.

D. Control on intermediate products

N.A.

E. Control Tests on the Finished Product

The lyophilizate product' specification controls the relevant parameters for the pharmaceutical form. The tests in the specification of the solvent product and their limits have been justified and are considered appropriate to adequately control the quality of the product. The specification of the reconstituted product is acceptable.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data of the lyophilized and the solvent products from the proposed production site have been provided demonstrating compliance with the specification.

Duomyxin	NL/V/0381/001/DC
Domes Pharma	DCP
	Publicly available assessment report

F. Stability

The stability data from the active substance manufacturers are provided in the corresponding CEPs for Neomycin sulfate and Polymyxin B sulfate.

Stability data have been provided in accordance with applicable European guidelines. All results are within the proposed specification limits. The proposed shelf-life of 36 months without any special storage condition is acceptable.

In-use stability data have been provided. The proposed in-use shelf life of 10 days is accepted. Additional in-use stability data at the end of shelf life will be provided in due course.

G. Other Information

N.A.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a hybrid application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological, pharmacological and clinical tests are not required.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users / the environment / consumers. Additional statements have been added, based on increased knowledge and the current state of science. Adverse events, warnings and contraindications are indicated in the SPC.

III.A Safety Testing

User Safety

Being a hybrid procedure the applicant refers to the reference product for information on this section.

Additionally, the applicant has provided a user safety assessment in compliance with the relevant guideline. Combined with increased knowledge and the current state of science, warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the VICH Guideline on Environmental Impact Assessment (EIAs) for Veterinary Medicinal Products- Phase I (CVMP /VICH/592/98-FINAL) and the supporting CVMP technical guidance document (EMA/CVMP/ERA/418282/2005-Rev.1- Corr.).

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the product is for topical ocular use in dogs and cats, not intended for human consumption and a Phase II assessment is not deemed necessary.

Duomyxin	NL/V/0381/001/DC
Domes Pharma	DCP
	Publicly available assessment report

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a hybrid application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

Tolerance in the Target Species of Animals

Additionally to the above, based on increased knowledge and the current state of science, warning statements and precautions have been added to the product literature ensuring safety to the target animals. Adverse events, warnings and contraindications are indicated in the SPC.

Resistance

Adequate warnings and precautions appear on the product literature.

V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when DUOMYXIN, 3 400 IU/ml / 10 000 IU/ml, Eye drops, powder and solvent for solution for dogs and cats is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of DUOMYXIN, 3 400 IU/ml / 10 000 IU/ml, Eye drops, powder and solvent for solution for dogs and cats for humans and the environment is acceptable.

Duomyxin	NL/V/0381/001/DC
Domes Pharma	DCP
	Publicly available assessment report

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicines Agencies website (www.HMA.eu) and in the Union Product Database (UPD).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None

Summary of change (Type; application number)	Section updated in Module 3	Approval date
NL/V/0381/001/E/001 New CMS: EL, PL, RO, SE	N/A	23 October 2023
NL/V/0381/001/A/001	IIF	2 July 2025